What the FDA labels say about taking them together
Amiodarone and azithromycin
Azithromycin's FDA label of December 4, 2025 names amiodarone in its warnings and precautions section; the amiodarone labels PlainMeds reads (2) do not name azithromycin. The azithromycin label: “Providers should consider the risk of QT prolongation which can be fatal when weighing the risks and benefits of azithromycin for at-risk groups including: patients with known prolongation of the QT interval, a history …”
Check it at the source: the amiodarone FDA label on DailyMed (effective December 9, 2025, Chartwell RX, LLC); the azithromycin FDA label on DailyMed (effective December 4, 2025, Bionpharma Inc.).
What does the amiodarone label say about azithromycin?
Amiodarone's label (effective December 9, 2025) and its 1 other brand-application label do not name azithromycin in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Amiodarone Hydrochloride), Chartwell RX, LLC, effective December 9, 2025 (SPL set 5520f11d-968d-4f4f-bf57-d14369c0d746), via openFDA; the full label on DailyMed
What does the azithromycin label say about amiodarone?
Azithromycin label, warnings and precautionsProviders should consider the risk of QT prolongation which can be fatal when weighing the risks and benefits of azithromycin for at-risk groups including: patients with known prolongation of the QT interval, a history of torsades de pointes, congenital long QT syndrome, bradyarrhythmias or uncompensated heart failure patients on drugs known to prolong the QT interval patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
Zithromax label (Pfizer Laboratories Div Pfizer Inc, July 24, 2026), warnings and precautionspatients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
Source: FDA drug label (Zithromax, NDA050711), Pfizer Laboratories Div Pfizer Inc, effective July 24, 2026 (SPL set db52b91e-79f7-4cc1-9564-f2eee8e31c45), via openFDA
Source: FDA drug label (Azithromycin), Bionpharma Inc., effective December 4, 2025 (SPL set 859bb02c-a4bc-46fa-9fc9-def1219b5dfb), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Amiodarone | Azithromycin | |
|---|---|---|
| Labeled for | n/a | Bacterial infections |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.122 per tablet 200 mg tablet | $0.266 per tablet 250 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once